Investors & MediaVectivBio AG is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. We are committed to pursuing severe rare diseases with well-defined biology that can be targeted with therapies that have the potential to meaningfully transform and improve the lives of patients.
Recent News and Upcoming Events
Oct 20, 2021
VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease
-FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease - Dosing of first patient expected in 1Q 2022 - - Interim data anticipated in 2H 2022 - - FDA previously granted orphan drug designation for apraglutide for the prevention of acute graft-versus-host disease - BASEL,